Mid-stage data advance Adaptimmune’s cell therapy pipeline

Adaptimmune Therapeutics (Nasdaq: ADAP) reported promising data Wednesday from its pivotal Phase II trial of lete-cel in certain solid tumors with few effective treatments.

The results, unveiled at the annual meeting of the Connective Tissue Oncology Society in San Diego, relate to treatment of synovial sarcoma and myxoid/round cell liposarcoma (MRCLS).

The data show that 42% of patients treated with lete-cel achieved a response. In synovial sarcoma, the median response lasted over 18 months, while in MRCLS, the median was just over a year. Safety data reflected known side effects, with no new concerns.